Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Shalini Andersson, PhD Senior Director, Drug Metabolism & Pharmacokinetics at AstraZeneca


Shalini is Senior Director and Head of Drug Metabolism & Pharmacokinetics within the Cardiovascular and Metabolic Disease Innovative Medicines unit (CVMD IMED) since December 2010. She is also a member of the Management Team for CVMD IMED as well as of the Review Board for CVMD projects. Shalini is also leading the open innovation collaboration with Ionis Pharmaceuticals and is project lead for subcutaneous delivery of modified RNA to man.

Prior to this role, Shalini held several leadership roles within CVMD Medicinal Chemistry including Head of Enabling Technologies and Head of Lead Optimization focused on developing world class platforms for design, synthesis, purification and analysis of small molecules for Drug projects.

Shalini received her PhD in 1989 at the University of Linköping, Sweden and was a research fellow at the Institute of Pharmaceutical Chemistry, University of Münster, Germany. Between 1990-1997 she held various research and teaching positions at the University of Linköping including Associate Professor in Organic and Analytical Chemistry. She joined AstraZeneca in 1997. She is the author or co-author of over 35 peer reviewed articles, 2 book chapters and 4 patents.

Agenda Sessions